Drug Discovery - Medicine.net

Drug Discovery

Sub Categories on Drug Discovery

{{items.name}}

Latest Articles

Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients

Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients

Updated on: October 06,2025

Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients

Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients

Updated on:October 06,2025

First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

Updated on: October 05,2025

First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer

Updated on:October 05,2025

Is multicancer testing valuable? Questions to ask before getting screened

Is multicancer testing valuable? Questions to ask before getting screened

Updated on: October 05,2025

Is multicancer testing valuable? Questions to ask before getting screened

Is multicancer testing valuable? Questions to ask before getting screened

Updated on:October 05,2025

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs

Updated on: October 05,2025

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs

Updated on:October 05,2025

Repurposing a diabetes medication to prime CAR T cancer targets

Repurposing a diabetes medication to prime CAR T cancer targets

Updated on: October 05,2025

Repurposing a diabetes medication to prime CAR T cancer targets

Repurposing a diabetes medication to prime CAR T cancer targets

Updated on:October 05,2025

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Updated on: October 05,2025

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Updated on:October 05,2025

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Updated on: October 05,2025

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Updated on:October 05,2025

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy

Updated on: October 05,2025

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy

Updated on:October 05,2025

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Updated on: October 05,2025

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Clinical trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

Updated on:October 05,2025

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

Updated on: October 05,2025

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

No OS benefit for concurrent and consolidative durvalumab vs. consolidation alone in unresectable stage 3 NSCLC: Trial

Updated on:October 05,2025

Categories

Allergy&Clinical immunology

Anesthesiology & Pain

Cardiovascular Diseases

Diabetes & Endocrinology

Emergency Medicine & Critical Care

Family Medicine

Gastroenterology

General Surgery

Hematology&Oncology

Infectious Diseases

Nephrology & Urology

Orthopedics & Sports medicine

Plastic Surgery

Psychiatry & Mental Health

Public Health & Prevention